Searched for
MANKIND PHARMA RESULTS
Mankind Pharma joins hands with Denovo Sciences for AI-powered drug discoveryMankind Pharma has joined forces with Denovo Sciences to revolutionize drug discovery using artificial intelligence. This strategic partner...- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Mankind Pharma profit jumps 30% on chronic therapy demand in Q4Mankind Pharma announced a significant 30 percent profit increase for the fourth quarter. This growth was fueled by strong demand for chron...
- Red alert: 15 stocks most vulnerable to FII selling as DIIs refuse to step inForeign institutional investors have divested approximately $53 billion from Indian equities since September 2024, leading to significant o...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Buy capital goods on dips, stay cautious on IT and consumption: Sudip BandyopadhyayMarket expert Sudip Bandyopadhyay outlines investment strategies across key sectors. He sees opportunities in State Bank of India and a gen...
- Smallcaps & midcaps rally! Firstsource Solutions, Nuvama, Godfrey Phillips, other stocks jump up to 16%Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...
- Mankind Pharma shares jump 2% as Morgan Stanley initiates coverage with Overweight call. Check target, upsideMankind Pharma share price surged 2% after Morgan Stanley initiated coverage with an 'Overweight' rating and a Rs 2,500 target price, citin...
- Mankind Pharma shares in focus after Q3 net profit rises 8%YoY to Rs 414 croreThe company reported an 8% year-on-year rise in Q3FY26 net profit to Rs 414 crore, while revenue grew 11.5% to Rs 3,567 crore, led by solid...
- Mankind Pharma shares in focus after Q3 net profit drops 16% YoY to Rs 385 croreMankind Pharma's shares are in focus following a 16.5% YoY decline in Q3 net profit to Rs 385 crore, despite strong revenue growth of 24%. ...
- Mankind Pharma Q3 Results: Profit falls 16% to Rs 384 croreMankind Pharma on Thursday said its consolidated net profit declined 16.5 per cent to Rs 384 crore in the third quarter ended December 31, ...
- Mankind Pharma shares gain over 6% as profit jumps nearly 30% in Q2Mankind Pharma's shares surged by 6% after reporting a 29% rise in Q2 profits, reaching ₹658.88 crore. The company attributed this growth t...
- Mankind Pharma Q4 Results: Net profit jumps 62% YoY to Rs 477 croreMankind Pharma on Wednesday reported 62% year-on-year (YoY) jump in net profit to Rs 477 crore in Q4FY24 led by strong domestic formulation...
- Mankind Pharma Q4 Results: PAT zooms 62% YoY to Rs 477 crore, revenue jumps 19%Mankind Pharma Q4 Results: The revenue from operations stood at Rs 2,441 crore versus Rs 2,053 crore reported in the year-ago period. Its b...
- Mankind Pharma shares jump 9% post Q1 earnings. Should you buy?The domestic business reported a robust 14% YoY growth in the quarter. The secondary sales saw an impressive growth of 12.5%, thereby outpe...
- Mankind Pharma Q1 Results: PAT soars 66% YoY to Rs 487 crore on strong all-round showOperating profit, calculated as earnings before interest, taxes, depreciation and amortisation (EBITDA) for the quarter surged 43% YoY to R...
- Mankind Pharma Q4 Results: Cons PAT jumps 50% YoY to Rs 285 crore, sales up 19%For FY23, the company reported a 11% drop in consolidated net profit to Rs 1,282 crore, despite a 12.4% growth in revenue to Rs 8,749 crore.
Load More
